Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Clinical trial NCT03134222 · COMPLETED
Trial details
- NCT number
- NCT03134222
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-24
- Primary completion
- 2019-03-13
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.